GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...

Guggenheim analyst Seamus Fernandez downgraded GSK (GSK) to Neutral from Buy without a price target following the Q3 report. While the company’s guidance appears achievable and it is a ...

GSK confirmed this morning that the disappointing readout from the DREAMM-3 trial of multiple myeloma therapy Blenrep reported earlier this month means that it will take the drug off the US market.

A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...

The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to ... and I'm delighted that we filed Blenrep in Europe, Japan, and the U.S ...

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to ...

Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster ... five major new product approval opportunities next year.” Blenrep, a treatment for cancer, and asthma medicine Depemokimab ...

Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy ... planning launches for five major new product approval opportunities next year.” Blenrep, a treatment for cancer, and asthma ...